ML signed the awaited deal for its inhaler drug last week. expect the announcement in a week.

In the Telegraph
ML Labs chairman survives rebel vote
By Harriet Meyer (Filed: 28/02/2005)
Stuart Sim was still executive chairman of the biotechnology company ML Laboratories last night after he survived a special board meeting called to discuss his potential ousting.
The meeting was convened to debate calls from rebel shareholders to remove Mr Sim and install in his place Ian Kent, a well-known figure in the biotech industry who has held senior roles in industry and Government. The rebels want also want another familiar biotech figure, Kieran Murphy, as chief executive.
However, no decision was taken on either at the meeting, though it is understood that Mr Sim is still likely to leave and to be replaced. Among the issues are Mr Sim's compensation, as, under his two-year contract, he is entitled to about 640,000, twice his annual salary.
The rebels represent more than 40pc of ML's shares and are headed by Jersey-based property investor David Kirch and advised by Code Securities. The company's shares have fallen from 267 in 2001 to 19p on Friday. It ran out of capital last year and was forced to raise 14m in an emergency fundraising.
Mr Sim became chief executive of ML in 1997. He became executive chairman in 2002.

It might help placate shareholders by ousting the present directors, but will the company be better served by a replacement?
Firstly he will need to be even-better rewarded and will need to increase turnover where none existed - but any new sales team will be expensive to set-up. So what will he do?
Sell the businesses is one cry I've heard, but is there likely to be anyone that wants them (unless going cheap = below their current value) - and their value is already low due (we are told) to the lacklustre efforts of the Board.

I have held this since it was over 1 and it's been a long downward drift. I went to one agm and was less than impressed, but the sp was bouyed by market excess and I didn't spot the flaw.....that if I don't get a good vibe then I should pull out.

Any new regeme should boost the sp if it can address the past failures and if it only boosts the sp a little current buyers will be satisfied. Those who hold long-term might as well forget this share - it's not likely to reach those levels again as anything that's sold will remove turnover and profit...to the point where we have nothing of any real value.

I resent termination packages that Directors award themselves - it should be related to the sp performance - if the shares rise he's entitled to the package (and no more) if the fall he gets nothing. Why should shareholders lose their shirts when the creator of the problem goes away in a new yacht? It really is time all such contracts had to contain fall-back positions for falling sp. All we need to see is legislation that says when a company offers shares outside the directors own holding, any contract for salary bonus/options/pension provision/loss of contract must balance the maximum reward payable if the company capitalisation rises tenfold and a scaling back in-line with any reducion in market capitalisation. (subject to comparison with FTSE100, say))

With sims staying on board, there must be something on the boil. Offer? merger? or good news ? There must be rns very soon. LOL

Yeah , like there has been every other month for the past five years. Wouldn't you stay on board if you were being paid 100 times what your performance deserved ?

Lets see what tomorrow brings.

Whatever it is it has sod all to do with Sims staying on board for the good of shareholders ... he's an overpaid disaster imo.

Is it his fault he is over paid? I do agree with you Dil

Well it aint mine :-)

Personally Dil I think a lot of games are being played behind the scenes. Straight talking is what is required if things are going to get any better !!

Fully agree with hangon
pay by preformance only, shareholders would welcome
high saleries if they were being rewarded by an increase
in profit and share price, but as usual shareholders get
stuffed sideways with no redress on the board it would seem.
Then when they ousted for non preformance they expect a kings
ransom for there trouble meanwhile shareholders have to suffer
for years just to recoup thier investment as is the case with ML

regards - long term investor still 57% down - pissed right off.
Will it ever bear any good news or will it come to shareholders
to stump up yet more millions just to pay the boards wages.

M.L. Laboratories PLC
03 March 2005

Embargoed Until 0700 3 March 2005


ML Laboratories PLC
('ML' or 'the Company')

Board Restructuring

The employment of Stuart Sim, ML's Executive Chairman, has been terminated by
the Board, and Mr Sim has ceased to be a director, with immediate effect.

The Company also announces that Mr Ian Kent and Mr Kieran Murphy have joined the
board as Executive Chairman and Chief Executive respectively.

Mr Kent was a director of Biofocus PLC from 2001 to 2003 and of Vernalis PLC
from 2002 to 2003. Mr Murphy was a director of Cobequid Life Sciences, a public
company quoted in Canada, from 1998 to 2000.

There are no other details to be disclosed pursuant to paragraphs 16.4(a) and
(b) of the Listing Rules.

- Ends -

Enquiries:

ML Laboratories PLC
Ian Kent, Executive Chairman 01223 303309
Peter Shennan, Finance Director 01925 844700

Weber Shandwick Square Mile
Kevin Smith 020 7067 0700



This information is provided by RNS
The company news service from the London Stock Exchange

Its Clarke Kent they need.

I think this is now the start of good things. The markets normally react favourably with a new appointment. Think I will top up again.

Glad I topped up. up 15% this morning.:)

I've held these for 18 months
Looks like the city likes the new management - up a further 9% today.
More positive news in the pipeline, i think my break even of 32p isnt too far away and from there who knows
Good luck

Chart looking better than it has in a very long time.

Good luck.

Rumours & Shakers 4/3/2005

Shares in ML Labs rose 2p to 23.25p today after specialist small cap website WatsHot.com reported market talk that someone might be stake-building in the healthcare technology group. It said that Thursday's announcement from the company that its chairman and chief executive had finally been ousted was expected - so why the large number of trades after the fact? Well, the word on the street is that someone has been making offers to big holders of the stock to purchase the shares at a premium to the current market price. Market talk suggests that a bidder is stake-building on the sidelines ahead of launching a full offer for the group.

We need some more news to keep this one going. LOL

M.L. Laboratories PLC
15 March 2005


Embargoed until 0700 GMT 15 March 2005

ML Laboratories PLC
('ML' or 'the Company')

ML's CLICKHALER APPROVED IN JAPAN

ML Laboratories plc (MLB.L) announced today that its respiratory subsidiary,
Innovata Biomed ('IB') has received news from its licensee Otsuka Pharmaceutical
Co, Ltd. that its Meptin Clickhaler product has been approved in Japan.

Under the terms of its Agreement with Otsuka, IB will receive a milestone
payment on approval. Clickhalers will be supplied to Otsuka on a commercial
basis. It is anticipated that Meptin Clickhaler will be introduced to the market
later in 2005.

Commenting for IB, Paul Ballington, Managing Director noted, 'This is a
significant event for IB, and demonstrates how products incorporating our
technologies can be successfully developed in the hands of our licensees. Otsuka
is a powerful competitor in the Japanese asthma market and a valuable licensee
for Clickhaler.'
- ends -

Enquiries:
Innovata Biomed Limited
Paul Ballington, Managing Director 01727 837341

www.innovata-biomed.com


Weber Shandwick Square Mile 020 7067 0700
Kevin Smith / Yvonne Alexander

Notes to Editors

ML Laboratories plc

ML is a pharmaceutical product development company with a track record of
successful clinical development, regulatory approval and licensing of
pharmaceutical products and which has a pipeline of future products targeted at
specialist markets. ML's activities are supported by a growing income stream
from marketed products it has successfully developed and licensed to other
pharmaceutical companies, which include Baxter, Shire, Celltech, Otsuka and
Pliva.

New therapeutic products in clinical development include a phosphate binder to
assist the management of kidney failure, treatments for prostate cancer and skin
cancer and a pain management compound. ML's technologies include unique
mechanisms for use in the discovery and manufacture of biotechnology products.

In addition ML provides inhaled drug delivery solutions to the global
pharmaceutical industry through its dedicated respiratory subsidiary Innovata
Biomed (IB).

Innovata Biomed

IB is a leading independent provider of inhaled drug delivery technologies to
the pharmaceutical industry. IB's proven delivery technologies are available for
proof of principle testing and as 'fast-to-market' drug delivery solutions.



This information is provided by RNS
The company news service from the London Stock Exchange

If someone is going to make a bid for this company they better do it soon before too much good news comes out.DYOR